Related Experiment Videos
Beta 2-microglobulin levels in cerebrospinal fluid of children with leukemia and lymphoma
Insights
Cerebrospinal fluid beta 2-microglobulin is not a reliable marker for diagnosing central nervous system metastases in children with cancer. Transient elevations may occur after specific therapies.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Biomarker Research
Background:
- Beta 2-microglobulin (B2M) is a protein found on cell surfaces.
- Elevated B2M levels can indicate cell turnover or inflammation.
- Its utility in diagnosing central nervous system (CNS) metastases in pediatric malignancies requires investigation.
Purpose of the Study:
- To evaluate the diagnostic value of cerebrospinal fluid (CSF) beta 2-microglobulin (B2M) for CNS metastases in children.
- To assess if CSF B2M levels correlate with the presence of meningeal leukemia or other CNS involvement.
- To investigate potential transient elevations of CSF B2M following specific therapeutic interventions.
Main Methods:
- Analysis of 491 CSF and 202 serum specimens from 119 children with various malignant conditions.
- Measurement of beta 2-microglobulin (B2M) levels in CSF and serum.
- Comparison of B2M levels between patients and healthy controls.
- Correlation of B2M levels with diagnosed CNS disease (meningeal leukemia) and therapeutic interventions (intrathecal methotrexate and irradiation).
Main Results:
- Mean CSF and serum B2M levels in pediatric cancer patients were not significantly different from controls.
- No elevated CSF B2M was detected at the time of diagnosed CNS leukemia.
- Eleven patients showed transiently elevated CSF B2M without evidence of CNS involvement.
- Five patients receiving intrathecal methotrexate and irradiation showed transient B2M increases, not exceeding the reference range.
Conclusions:
- CSF beta 2-microglobulin (B2M) is not a useful diagnostic marker for CNS metastases in pediatric malignancies.
- Transient elevations in CSF B2M can occur following intrathecal methotrexate and irradiation therapy.
- Further research may explore other biomarkers for CNS involvement in pediatric cancers.
Abstract:
Beta 2-microglobulin levels were determined in the cerebrospinal fluid (CSF) of 119 children (ages 1 1/2 to 18 years) with malignant conditions; 87 with acute lymphoblastic leukemia, 9 with acute myeloblastic leukemia, 15 with lymphoma, and 8 with solid tumours. A total of 491 CSF specimens and 202 serum specimens were analyzed over a 12-month period. The mean CSF beta 2-microglobulin and serum beta 2-microglobulin were 1.11 +/- 0.58 mg/L and 1.5 +/- 0.64 mg/L respectively and were not different from the mean CSF (1.20 +/- 0.45 mg/L) and serum beta 2-microglobulin levels (1.70 +/- 0.45 mg/L) found in control patients. Meningeal leukemia was diagnosed on the basis of cytology in 7 patients. No elevation of CSF beta 2-microglobulin was found in any specimen at the time of CNS disease. Eleven other patients showed a transient rise in CSF beta 2-microglobulin above the reference range (greater than 2.1 mg/L). No evidence of CNS involvement was found in any of these patients. Five of these patients had received a combination of intrathecal methotrexate and irradiation therapy within the previous 4 months. A transient rise in CSF beta 2-microglobulin (2-3-fold increase over baseline CSF levels), which did not exceed the upper limit of the reference range was seen in 5 of 7 other children receiving the above therapy. Our study fails to demonstrate the usefulness of CSF beta 2-microglobulin for the diagnosis of CNS metastases but suggests that a transient elevation of CSF beta 2-microglobulin may occur after intrathecal methotrexate and irradiation therapy.